INTRODUCTION
============

Platelets are essential for primary hemostasis and repair of the endothelium ([@b1-pnf018-03-05],[@b2-pnf018-03-05]), but they also play a role in the development of cardiovascular diseases such as atherosclerosis and thrombotic events ([@b3-pnf018-03-05]). When a blood vessel is damaged by injury or pathological alterations, such as in atherosclerosis, platelets adhere to the site of vascular injury, which triggers the subsequent platelet activation followed by platelet aggregation ([@b4-pnf018-03-05]). During platelet aggregation, additional platelets are recruited from the circulation to the site of injury, causing the formation of an occlusive platelet thrombus ([@b4-pnf018-03-05]). The recruitment of additional platelets is mediated by a variety of stimuli that are produced or released from activated platelets, including adenosine diphosphate/adenosine triphosphate (ADP/ATP), thromboxane A~2~ (TXA~2~) and serotonin, which amplify and sustain the initial platelet response, recruit circulating platelets and thereby, promote thrombus growth and stability ([@b5-pnf018-03-05]).

Blood coagulation is also an important part of hemostasis, which refers to secondary hemostasis. Platelets stimulate the blood coagulation cascade at the site of vascular injury, which leads to the generation of a fibrin-containing clot to stop the bleeding and repair the damaged vessel ([@b6-pnf018-03-05],[@b7-pnf018-03-05]). The coagulation cascade is initiated by two pathways, known as the intrinsic pathway and extrinsic pathway ([@b8-pnf018-03-05]). The intrinsic pathway is initiated by substances within the damaged blood vessel, whereas the extrinsic pathway is activated when blood is exposed to tissue factors from the surface of extravascular cells. Regardless of which pathway is activated, the end result of both is the generation of factor Xa, which then catalyzes the conversion of prothrombin, an inactive form of thrombin, to thrombin ([@b9-pnf018-03-05],[@b10-pnf018-03-05]). Thrombin, in turn, converts fibrinogen to fibrin, which promotes platelet aggregation at the site of vascular injury and causes vascular atherothrombotic disorders ([@b8-pnf018-03-05]--[@b10-pnf018-03-05]). Accordingly, the inhibition of platelet activation and coagulation is considered a strategy for the treatment of thrombotic diseases. However, many drugs, which are chemically or biologically synthesized, with antiplatelet and anticoagulant functions have a variety of adverse effects including hemorrhaging, neutropenia, agranulocytosis, thrombotic thrombocytopenia and gastrointestinal upset ([@b11-pnf018-03-05]--[@b13-pnf018-03-05]). Thus, in recent years, much attention has been given to the development of herbal medicines for treating cardiovascular diseases, due to their safety and eco-friendly image ([@b14-pnf018-03-05],[@b15-pnf018-03-05]).

*Artemisia princeps* Pampanini (AP) is an herbaceous plant that is widely used as Korean, Chinese, and Japanese traditional medicine for the treatment of multiple disorders including colic, diarrhea, and irregular uterine bleeding ([@b16-pnf018-03-05]). The ethanol extract of AP (EAP) exhibited anti-atherosclerotic and anti-inflammatory activities in LDL receptor knockout mice ([@b17-pnf018-03-05]). Jaceosidin isolated from AP methanolic extracts inhibited LDL oxidation, reactive oxygen species generation and inflammation *in vitro*([@b18-pnf018-03-05]). Our previous experiments have also found that EAP and its main flavonoids, eupatilin and jaceosidin, reduced the plasma lipids levels as well as fasting blood glucose level in animals and subjects with type 2 diabetes ([@b19-pnf018-03-05]--[@b21-pnf018-03-05]). However, little is known about the antiplatelet and anticoagulation effects of EAP. Thus, we investigated whether EAP and its major flavonoids, eupatilin and jaceosidin, could modulate platelet activation and blood coagulation *in vitro*.

MATERIALS AND METHODS
=====================

Materials
---------

*A. princeps* Pampanini was harvested in Ganghwa County and the leaves were collected from air-dried whole plants. The leaves were extracted with 70% ethanol, and concentrated under reduced pressure. The concentrated solution was freeze-dried to powder. After freezing at −40°C, the frozen matrix was dried from 0°C\~30°C in a programmable freeze dryer (PVTFD 100R, Ilshin Lab., Gyeonggi, Korea). The yield of the ethanol extract of *A. princeps* Pampanini was 17.6%, producing 4.7 kg of dried ethanol extract from 26.67 kg of powdered leaves.

The quantities of the two major flavonoids, eupatilin and jaceosidin, present in the freeze-dried ethanol extract of the leaves were assayed by high-performance liquid chromatography on an Agilent 1100 series system (Agilent Technologies, Santa Clara, CA, USA) using a Venusil XBP C18 column (4.6×250 mm, film thickness 5 μm; Bonna-Agela Technologies, Wilmington, DE, USA). The mobile phase using isocratic elution was a solvent mixture of 65% methanol containing 0.1% trifluoroacetic acid. The flow rate was 1.0 mL/minute with an injection volume of 10 mL, and ultraviolet detection was performed at 330 nm. According to these measurements, 1 g of freeze-dried ethanol extract from the leaves contained 9.7 mg of eupatilin and 6.6 mg of jaceosidin. As shown in the HPLC chromatograms of mixed standard compounds and extract in [Fig. 1](#f1-pnf018-03-05){ref-type="fig"}, the quantification of the two major flavonoids was determined by the calibration curve. Eupatilin and Jaceosidin were purchased from NPC BioTech. (Daejon, Korea). EAP, eupatilin and jaceosidin were dissolved in dimethyl sulfoxide (DMSO) for the *in vitro* test.

Arachidonic acid, ADP and collagen were purchased from Chrono-log Corporation (Chicago, IL, USA). aPTT and PT reagents were purchased from Fisher Diagnostics (Middletown, VA, USA).

Preparation of human platelets
------------------------------

Whole blood was collected from 6 healthy male volunteers (20\~35 years old) into 3.2% sodium citrate Vacutainer (Becton-Dikinson, Franklin Lakes, NJ, USA) and heparin Vacutainer (Becton-Dikinson) blood collection tubes, separately. The citrated whole blood was centrifuged for 10 min at 1,000×*g*. The supernatant fraction platelet-rich plasma (PRP) was used for the aggregation study. One-half of the PRP fraction was further centrifuged for 5 min at 2,000×*g* at room temperature and its supernatant was obtained as platelet-poor plasma (PPP). A small aliquot of fresh PPP was used to measure AA-, ADP- and collagen-induced platelet aggregation. The rest of the PRP fraction was stored at −80°C until the anticoagulant activity and serotonin concentration were measured. The heparin-treated blood was centrifuged for 10 min at 1,000×*g*, and the resultant plasma was then stored at −80°C until the TXA~2~ concentration was measured. All experiments were conducted at least four times. Experiments were performed according to the guidelines of the Ethics Committee of Kyungpook National University.

*In vitro* platelet aggregation assay
-------------------------------------

Platelet aggregation was determined by the turbidimetry method using an aggregometer (Chrono-Log Co., Havertown, PA, USA). The PRP (250 μL) was pre-incubated with various concentrations of EAP, eupatilin and jaceosidin for 10 min at 37°C, and platelet aggregation was stimulated by adding collagen (2 μg/mL), ADP (5 μM) and arachidonic acid (AA, 0.5 mM). The platelet aggregation was monitored for 7 min using an aggregometer with constant stirring at 1,000 rpm and expressed as the percent change in light transmission. Light transmission of PRP represented 0% and PPP represented 100%. This measurement for platelet aggregation was performed in less than 2 h.

Measurement of serotonin generation
-----------------------------------

The serotonin concentration was measured using a commercial serotonin ELISA kit (MyBioSource, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, after preincubation of PRP with EAP, eupatilin or jaceosidin for 20 min at 37°C, PRP was acylated by the acylation reagent, and the acylated plasma (25 μL) and serotonin antiserum (100 μL) were incubated for 30 min at room temperature. After washing the plates, a conjugate (anti-rabbit IgG conjugated with peroxidase) (100 μL) was added into the plate and further incubated for 15 min at room temperature. Thereafter, substrate (tetramethylbenzimide, TMB) (100 μL) for ELISA detection and stop solution (0.25 M H~2~SO~4~) were added and the absorbance was monitored at 450 nm for 5 min.

Measurement of TXB~2~ generation
--------------------------------

The generation of TXA~2~ in platelets was measured by determining the TXB~2~ concentration, because TXA~2~ is unstable and is quickly converted to TXB~2~, using a commercial TXB~2~ ELISA kit (MyBioSource). After a suspension of PRP was preincubated with various concentrations of EAP, eupatilin and jaceosidin for 20 min at 37°C, the plasma in the plates was incubated for 2 h at 37°C. Antibodies (Biotin-antibody) (100 μL) were added to the mixture and incubated for 1 hour at 37°C. Then, horseradish peroxidase (100 μL) was added and further incubated for 1 hour at 37°C. Thereafter, the substrate (tetramethylbenzimide, TMB) (100 μL) was added to the mixture. H~2~SO~4~ was added to stop TXA~2~ generation and the stable metabolite of TXA~2~ was determined according to the manufacturer's instructions.

*In vitro* anticoagulation assay
--------------------------------

The activated partial thromboplastin time (aPTT) and prothrombin time (PT) were determined using a Thrombotimer (Behnk Elektronik, Norderstedt, Germany) according to the manufacturer's instructions. In brief, PRP (90 μL) was incubated with various concentrations of EAP, eupatilin or jaceosidin (10 μL) for 3 min at 37°C and then aPTT reagent (100 μL) was added to the mixture and incubated for 3 min at 37°C. Thereafter, 20 μM CaCl~2~ (100 μL) was added and the clotting time was recorded. For the PT assay, PRP (90 μL) was incubated with various concentrations of EAP, eupatilin or jaceosidin (10 μL) for 3 min at 37°C. PT reagent was then added and the clotting time was recorded. PBS (phosphate buffered saline) was used as a control.

Statistical analysis
--------------------

All data were expressed as the means±standard error of mean (SEM) of at least four different experiments. SPSS (version 18, SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis. Significant differences between groups were analyzed with the Student's t-test. Differences were considered to be statistically significant when *P*\<0.05.

RESULTS
=======

Effects of EAP and its major flavonoids, eupatilin and jaceosidin, on antiplatelet aggregation *in vitro*
---------------------------------------------------------------------------------------------------------

We evaluated the antiplatelet activity of EAP and its major flavonoids against AA (0.5 mM), ADP (5 μM) and collagen (2 μg/mL)-stimulated platelet aggregation ([Table 1](#t1-pnf018-03-05){ref-type="table"}). The AA-induced platelet aggregation was significantly reduced by EAP (1 mg/mL), eupatilin (10 μM) and jaceosidin (10 μM). However, ADP- and collagen-induced platelet aggregation was not altered by EAP and its major flavonoids.

Effects of EAP and its major flavonoids, eupatilin and jaceosidin, on serotonin generation
------------------------------------------------------------------------------------------

The serotonin concentration was measured to investigate whether EAP and its major flavonoids could attenuate serotonin generation. As shown in [Fig. 2](#f2-pnf018-03-05){ref-type="fig"}, EAP at concentrations of 1 and 2 mg/mL significantly and dose-dependently attenuated serotonin generation. Moreover, both eupatilin and jaceosidin significantly inhibited serotonin generation at or greater than 0.5 μM in a dose-dependent manner.

Effects of EAP and its major flavonoids, eupatilin and jaceosidin, on TXB~2~ generation
---------------------------------------------------------------------------------------

EAP and its major flavonoids were tested to determine whether they could inhibit the generation of TXB~2~. EAP significantly inhibited TXB~2~ generation at concentrations of 0.01 and 2 mg/mL significantly and dose-dependently ([Fig. 3](#f3-pnf018-03-05){ref-type="fig"}). Jaceosidin and eupatilin, the major bioflavonoids of EAP, also significantly inhibited TXB~2~ generation at concentrations higher than 0.5 μM.

Effects of EAP and its major flavonoids, eupatilin and jaceosidin, on anticoagulant activity
--------------------------------------------------------------------------------------------

To determine whether EAP and its major flavonoids have anticoagulant properties, PT and aPTT were evaluated using human plasma. EAP significantly prolonged PT and aPTT at or greater than 0.1 mg/mL in a dose-dependent manner ([Table 2](#t2-pnf018-03-05){ref-type="table"}). Among the major flavonoids of EAP, eupatilin significantly and dose-dependently prolonged aPTT and PT ([Table 3](#t3-pnf018-03-05){ref-type="table"}). However, jaceosidin only significantly prolonged PT at concentrations of 0.5, 1 and 30 μM.

DISCUSSION
==========

In recent years, some herbal medicines have been considered as potential novel antiplatelet and anticoagulant agents, and much attention has been focused on the identification of plant-based materials with antiplatelet and anticoagulant activities. In the present study, the antiplatelet and anticoagulant properties of EAP and its major flavonoids were examined. We first demonstrated that EAP and its major flavonoids, eupatilin and jaceosidin, can inhibit platelet activation and coagulation *in vitro*.

Abnormal platelet activation and aggregation play an important role in the development of thrombosis ([@b1-pnf018-03-05],[@b2-pnf018-03-05]). After vascular injury, platelet adhesion occurs at the site of vascular injury, which triggers platelet activation and subsequent thrombus formation via aggregation ([@b4-pnf018-03-05]). The process of platelet activation and aggregation can be enhanced and amplified by the cooperative actions of multiple factors, including AA, ADP, collagen, serotonin and TXA~2~. Among them, TXA~2~ and serotonin are released from activated platelets promoting the activation and recruitment of additional platelets. Thus, the inhibition of TXA~2~ and serotonin generation can lead to anti-thrombosis ([@b22-pnf018-03-05],[@b23-pnf018-03-05]). In the present study, we found that EAP and its major flavonoids, eupatilin and jaceosidin, significantly attenuated the generation of TXB~2~, a stable form of TXA~2~, and serotonin in a dose-dependent manner. In addition, eupatilin and jaceosidin, as well as EAP, markedly inhibited AA-induced platelet aggregation; however, they exhibited a relatively weak inhibitory effect on collagen and ADP-induced platelet aggregation, suggesting their selective inhibitory activity for the AA-induced platelet activation pathways. AA is a precursor of TXA~2~, prostaglandin and other eicosanoids. When exogenously applied to platelets, AA is metabolized to TXA~2~ by cyclooxygenase (COX) ([@b24-pnf018-03-05]). Aspirin, a well-known antiplatelet agent, is reported to inhibit platelet TXA~2~ generation and AA-induced platelet aggregation by inhibiting COX ([@b25-pnf018-03-05]). Several vegetables, such as spinach, garlic bolt, blanched garlic and Chinese leek, also inhibit COX and human platelet aggregation induced by AA *in vitro*([@b26-pnf018-03-05]). A number of polyphenols, including eupatilin and jaceosidin, are known inhibitors of COX-1 or COX-2 ([@b27-pnf018-03-05],[@b28-pnf018-03-05]). Thus, these data suggest that the inhibition of TXA~2~ generation and AA-induced platelet aggregation in presence of EAP could be mediated through the suppression of platelet COX activity, although we did not determine this activity. Also plausible is that eupatilin and jaceosidin are major bioactive components, which may contribute to the antiplatelet aggregation activity of EAP.

Blood coagulation and platelets are mutually dependent in their interactive processes of hemostasis and thrombosis. Many coagulation factors appear to bind to platelets and induce platelet activation during initiation of coagulation ([@b29-pnf018-03-05]). The concerted actions of coagulation factors on the platelet surface cause thrombin formation, so that a stable fibrin clot can be formed ([@b30-pnf018-03-05],[@b31-pnf018-03-05]). Accordingly, assessment of coagulation activation as well as platelet activation and aggregation is a strategy to examine thrombotic risk and blood circulation ([@b29-pnf018-03-05]). The aPTT and PT are by far the most common screening tests for coagulation abnormalities. Prolonged aPTT suggests inhibition of the intrinsic coagulation pathway, whereas prolonged PT suggests inhibition of the extrinsic coagulation pathway ([@b32-pnf018-03-05]). We found that EAP as well as eupatilin prolonged the coagulation parameters such as PT and aPTT *in vitro*. Jaceosidin also significantly prolonged PT but did not affect aPTT. These results possibly indicate that eupatilin with or without jaceosidin may be responsible for the anticoagulant activity of EAP.

In conclusion, this study showed that EAP inhibited the intrinsic and extrinsic pathways of blood coagulation, AA-induced platelet aggregation and the generation of TXA~2~ and serotonin *in vitro*. Eupatilin and jaceosidin, flavonoids present in EAP, also exhibited antiplatelet and anticoagulant effects, indicating that these flavonoids, especially eupatilin, may be responsible for the antiplatelet and anticoagulant property of EAP. These results are also supported by the quantitative HPLC analysis of eupatilin and jaceosidin. As referred in materials, 1.0 mg/mL of EAP contains 9.7 μg/mL of eupatilin and 6.6 μg/mL of jaceosidin and the concentrations are converted into 28 μM and 20 μM in 1 g of EAP, respectively. Because the concentrations of tested samples are similar (0.5 μM\~30 μM), EAP could possibly have synergistic effects compared to single compounds.

Together, our findings suggest that EAP may be useful in the prevention or improvement of vascular diseases, although further studies are required to elucidate the *in vivo* effects.
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![Isolation of natural compounds jaceosidin and eupatilin. The chemical structures of eupatilin (A) and jaceosidin (B). Analytical HPLC chromatograph of mixed standard compound (C) and EAP (D).](pnf018-03-05f1){#f1-pnf018-03-05}

![Effect of EAP and its major flavonoids on serotonin generation. Plasma was preincubated with various concentrations of EAP and its major flavonoids for 20 min at 37°C. The serotonin content was determined using an ELISA kit. (A) EAP (B) major flavonoids of EAP, eupatilin and jaceosidin. Data are the mean±SEM. ^\*\*^*P*\<0.01 vs. concentration of 0 μM. EAP, ethanol extract of *Artemisia princeps* Pampanini.](pnf018-03-05f2){#f2-pnf018-03-05}

![Effect of EAP and its major flavonoids on TXB~2~ generation. Plasma was preincubated with various concentrations of EAP and its major flavonoids for 20 min at 37°C. TXB~2~ content was determined using a TXB~2~ ELISA kit. (A) EAP (B) major flavonoids of EAP, eupatilin and jaceosidin. Data are the mean±SEM. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001 vs. concentration of 0 μM. EAP, ethanol extract of *Artemisia princeps* Pampanini; TXB~2~, thromboxane B~2~.](pnf018-03-05f3){#f3-pnf018-03-05}

###### 

Effects of EAP and its major flavonoids on AA-, ADP- and collagen-induced platelet aggregation

  Samples[1)](#tfn3-pnf018-03-05){ref-type="table-fn"}   Agonist-induced platelet aggregation (%)[2)](#tfn4-pnf018-03-05){ref-type="table-fn"}                
  ------------------------------------------------------ --------------------------------------------------------------------------------------- ------------ -----------
  Control                                                86.5±5.80                                                                               81.5±0.50    87.0±1.73
  EAP                                                    1.0±0.00[\*\*\*](#tfn2-pnf018-03-05){ref-type="table-fn"}                               74.5±6.50    85.7±2.08
  Eupatilin                                              0.7±0.58[\*\*\*](#tfn2-pnf018-03-05){ref-type="table-fn"}                               78.0±12.00   83.0±1.00
  Jaceosidin                                             1.0±0.00[\*\*\*](#tfn2-pnf018-03-05){ref-type="table-fn"}                               85.5±0.50    83.7±0.58

Data represent the mean±SEM.

*P*\<0.001 vs. control, DMSO was used as the control.

EAP, ethanol extract of *Artemisia princeps* Pampanini, 1.0 mg/mL; eupatilin, 10 μM; jaceosidin, 10 μM.

Concentration of agonists: AA, 0.5 mM; ADP, 5 μM; collagen, 10 μg/mL. Normal range of agonist-induced platelet aggregation (%): AA, 74\~99; ADP, 69\~88, collagen, 70\~94.

AA, arachidonic acid; ADP, adenosine diphosphate.

###### 

Effects of EAP on anticoagulant activity based on PT and aPTT

  Sample                                                  Concentration   PT (s)                                                       aPTT (s)
  ------------------------------------------------------- --------------- ------------------------------------------------------------ ------------------------------------------------------------
  PBS[1)](#tfn9-pnf018-03-05){ref-type="table-fn"}                        11.2±0.00                                                    26.3±1.6
  EAP                                                     0.1 mg/mL       13.4±0.06[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   36.2±2.46[\*\*](#tfn7-pnf018-03-05){ref-type="table-fn"}
                                                          0.25 mg/mL      13.4±0.35[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   36.5±2.13[\*\*](#tfn7-pnf018-03-05){ref-type="table-fn"}
                                                          0.5 mg/mL       13.9±0.00[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   37.9±1.63[\*\*](#tfn7-pnf018-03-05){ref-type="table-fn"}
                                                          1 mg/mL         14.2±0.60[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   38.4±1.03[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}
                                                          2 mg/mL         14.8±0.00[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   40.5±1.74[\*\*](#tfn7-pnf018-03-05){ref-type="table-fn"}
  Heparin[2)](#tfn10-pnf018-03-05){ref-type="table-fn"}   20 nM           43.9±1.80[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}   \>200[\*\*\*](#tfn8-pnf018-03-05){ref-type="table-fn"}

Data represent the mean±SEM.

*P*\<0.01,

*P*\<0.001 vs. control.

Phosphate buffered saline (PBS) was used as the control.

Heparin was used as the positive control.

EAP, ethanol extract of *Artemisia princeps* Pampanini; PT, prothrombin time; aPTT, activated partial thromboplastin time.

###### 

Effects of the major flavonoids of EAP on anticoagulant activity based on PT and aPTT

  Sample                                                  Concentration   PT (s)                                                        aPTT (s)
  ------------------------------------------------------- --------------- ------------------------------------------------------------- -----------------------------------------------------------
  PBS[1)](#tfn16-pnf018-03-05){ref-type="table-fn"}                       12.7±0.05                                                     30.7±0.90
  Jaceosidin                                              0.5 μM          13.0±0.20[\*](#tfn13-pnf018-03-05){ref-type="table-fn"}       31.5±0.17
                                                          1 μM            13.4±0.37[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}     31.0±0.72
                                                          5 μM            13.0±0.34                                                     29.3±1.24
                                                          10 μM           12.8±0.34                                                     30.1±0.58
                                                          30 μM           13.2±0.26[\*](#tfn13-pnf018-03-05){ref-type="table-fn"}       29.9±0.15
  Eupatilin                                               0.5 μM          13.3±0.46[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}     34.2±0.17[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}
                                                          1 μM            13.5±0.26[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}     34.4±0.05[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}
                                                          5 μM            13.6±0.32[\*](#tfn13-pnf018-03-05){ref-type="table-fn"}       36.4±0.11[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}
                                                          10 μM           13.6±0.29[\*\*\*](#tfn15-pnf018-03-05){ref-type="table-fn"}   37.6±0.15[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}
                                                          30 μM           13.7±0.23[\*\*\*](#tfn15-pnf018-03-05){ref-type="table-fn"}   38.8±0.10[\*\*](#tfn14-pnf018-03-05){ref-type="table-fn"}
  Heparin[2)](#tfn17-pnf018-03-05){ref-type="table-fn"}   20 nM           43.9±1.80[\*\*\*](#tfn15-pnf018-03-05){ref-type="table-fn"}   \>200[\*\*\*](#tfn15-pnf018-03-05){ref-type="table-fn"}

Data represent the mean±SEM.

*P*\<0.05,

*P*\<0.01,

*P*\<0.001 vs. control.

Phosphate buffered saline (PBS) was used as the control.

Heparin was used as the positive control.

PT, prothrombin time; aPTT, activated partial thromboplastin time.
